Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial
RCT (n=225) reports median event-free survival was prolonged by approximately 1year with deferasirox vs placebo (3.9 years [95% CI, 3.2 to 4.3 yrs] vs. 3.0 years [CI 2.2 to 3.7 yrs], respectively; HR 0.64 [CI 0.42 to 0.96]).
Source:
Annals of Internal Medicine
SPS commentary:
The study included patients with serum ferritin levels greater than 2247 pmol/L, prior receipt of 15 to 75 packed red blood cell units and no severe cardiac, liver, or renal abnormalities.
Event-free survival was defined as time from date of randomisation to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukaemia) or death.